Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study
Autor: | Sotirios Koutsounas, Georgia Vourli, Irini Vafiadis, Gregory Giannoulis, T. Vasiliadis, Athina Hounta, Nina Manolaki, George N. Dalekos, Georgia Nikolopoulou, Emanuel K. Manesis, George Germanidis, Giota Touloumi, George V. Papatheodoridis |
---|---|
Rok vydání: | 2013 |
Předmět: |
Adult
Male medicine.medical_specialty HBsAg Adolescent viruses medicine.disease_cause Serology Cohort Studies Young Adult Interquartile range Internal medicine Epidemiology Prevalence medicine Humans Longitudinal Studies Prospective Studies Child Prospective cohort study Hepatitis B virus Hepatitis B Surface Antigens Greece Hepatology Coinfection business.industry virus diseases Middle Aged biochemical phenomena metabolism and nutrition Hepatitis B medicine.disease Hepatitis D Child Preschool Multivariate Analysis Immunology Female Hepatitis D virus Hepatitis Delta Virus business Progressive disease Follow-Up Studies |
Zdroj: | Journal of Hepatology. 59:949-956 |
ISSN: | 0168-8278 |
Popis: | Hepatitis D virus (HDV) has decreased in Europe, but recent reports indicate a rising trend. We report the epidemiological changes, clinical progress, and effect of treatment on the natural course of HDV infection in Greece during the last 13 years.Prospective data were extracted from the HepNet.Greece Cohort-Study.Since 1997, 4673 chronic HBV (CHB) cases (4527 adults, 146 children) have been followed prospectively. Two thousand one hundred thirty-seven patients were tested for anti-HDV [101 (4.7%) positive]. Anti-HDV testing in Greece decreased significantly (57.0% before 2003, 35.3% thereafter; p0.001). Anti-HDV prevalence among HBsAg-positives was 4.2%; lower in native Greeks (2.8%) than in immigrants (7.5%) or in children (15.3%; p0.001). Within 2.3 years of follow-up, HDV occurred in 11/2047 HBsAg-positive patients (2.2 new delta-infected adults and 8.7 children per 1000 HBsAg-positive annually). HDV-positive compared to CHB adults were younger (p=0.035) and had more active and advanced disease at baseline, as indicated by laboratory indices and the higher prevalence of cirrhosis at younger age. During a 4.2-year median observation, significantly more anti-HDV-positive than CHB adults developed a liver-related first event (20.0% vs. 8.5%, p Log-rank=0.014).Treatment was received by 46/90 (51.1%) patients, 40 of them interferon-based. In multivariable analysis, interferon significantly decreased disease progression in HDV-positive patients [HR=0.14 (95% CI: 0.02-0.86; p=0.033)].In Greece, HDV serology is currently tested in only one-third of HBsAg-positive patients. HDV prevalence is lower in native Greeks compared to immigrants, who may contribute50% of the HDV infection burden in Greece. Data show that HDV infection is a rapidly progressive disease, but interferon-based treatment may alter its course. |
Databáze: | OpenAIRE |
Externí odkaz: |